Evidence map›Paper›PMID 40128489›Full record

ArticleCerebellum (London, England)2025

miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.

Carolina Alves Pereira Corrêa, Pablo Shimaoka Chagas, Mirella Baroni, Augusto Faria Andrade, Rosane Gomes de Paula Queiroz, Veridiana Kiill Suazo, Gustavo Alencastro Veiga Cruzeiro, Paola Fernanda Fedatto, David Santos Marco Antonio, Silvia Regina Brandalise and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Carolina Alves Pereira CorrêaDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Pablo Shimaoka ChagasDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Mirella BaroniDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Augusto Faria AndradeDepartment of Human Genetics, McGill University, Montreal, Canada.
Rosane Gomes de Paula QueirozDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, 14048-900, Brazil.
Veridiana Kiill SuazoDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, 14048-900, Brazil.
Gustavo Alencastro Veiga CruzeiroDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Paola Fernanda FedattoDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, 14048-900, Brazil.
David Santos Marco AntonioSeven Bridges Biotech Consulting, São Paulo, Brazil.
Silvia Regina BrandaliseBoldrini Children's Center, Laboratory of Molecular Biology, Campinas, Brazil.
José Andres YunesBoldrini Children's Center, Laboratory of Molecular Biology, Campinas, Brazil.
Rodrigo Alexandre PanepucciHemocentro Foudation, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Carlos Gilberto Carlotti JuniorDepartment of Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Ricardo Santos de OliveiraDepartment of Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Luciano NederDepartment of Pathology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Luiz Gonzaga ToneDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Elvis Terci ValeraDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, 14048-900, Brazil.
Carlos Alberto ScrideliDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. scrideli@fmrp.usp.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 471885/2013-4 and 406484/2022-8 - INCT BioOncoPedFundação de Amparo à Pesquisa do Estado de São Paulo 2010/07020-9 and 2014/20341-0
6 · The paper itself

Abstract

The tumorigenesis of medulloblastoma (MB), the most frequent malignant brain tumor in children, is not completely known. MicroRNA (miRNA) expression profiles have been associated with human cancers; however, the role played by miRNAs in pediatric MB has been poorly explored. Global miRNA expression in MB and non-neoplastic cerebellum samples was evaluated by microarray assay. Nine miRNAs (miR-31-5p, -329, -383, -433, -485-3p, -485-5p, -491, -512-3p, and 539-5p) in 51 pediatric MB and 7 pediatric non-neoplastic cerebellum samples were chosen for validation by qRT-PCR. The validated miRNAs were less expressed in the MB samples than in the non-neoplastic controls. In our cohort of patients, higher miR-512-3p expression was associated with incomplete degree of resection, classification as high risk, classification as group 4, and poor overall survival. In silico analysis in an independent cohort of MB patients identified that some of the miR-512-3p target genes were also correlated with prognostic features. Our results have shown that miR-512-3p could be associated with poor clinical outcomes in pediatric MB, suggesting that miR-512-3p is a potential biomarker of prognosis.

Indexed as

Biomarkers, TumorCerebellar NeoplasmsMedulloblastomaMicroRNAsAdolescentCerebellumChildChild, PreschoolCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansInfantMalePrognosisBiomarkers, TumorMicroRNAsCerebellumMedulloblastomaMicroRNA ProfilemiR-512-3p

Identifiers

PMID40128489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.